Shots:
- The company has launched Tyenne (biosimilar, Actemra) in the US, to treat chronic autoimmune diseases; got approved on Mar 05, 2024
- Tyenne, an Interleukin-6 (IL-6) receptor antagonist developed by using Fresenius’ analytical & manufacturing technologies to treat several autoimmune diseases incl. rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis & systemic juvenile idiopathic arthritis
- In addition to its available biosimilars, Idacio (adalimumab) & Stimufend (pegfilgrastim), company is growing its biosimilars pipeline with late-stage developments for oncology and autoimmune diseases
Ref: Fresenius Kabi | Image: Fresenius Kabi | Press Release
Related News:- Teva and Alvotech’s Selarsdi (Biosimilar, Stelara) Receives the US FDA’s Approval
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
